Resultado de búsqueda
12 de may. de 2021 · Published May 12, 2021. N Engl J Med 2021;384: 1800 - 1809. DOI: 10.1056/NEJMoa2034975. VOL. 384 NO. 19. Abstract. Background. Tezepelumab is a human monoclonal antibody that blocks thymic stromal...
- Free Full Text
The heterogeneous response to asthma treatment may be...
- New England Journal of Medicine
Biologic agents are efficacious add-on therapies for...
- The New England Journal of Medicine
This review outlines recent insights into type 2...
- Free Full Text
7 de may. de 2024 · The 2022 GINA Report is a comprehensive and practical resource about asthma based on a review of recent scientific literature. It contains new information about asthma diagnosis, treatment, prevention, and management, and forms the basis for other GINA documents and programs.
7 de may. de 2024 · The 2023 update of the Global Strategy for Asthma Management and Prevention provides new scientific information about asthma based on a review of recent literature. It is a comprehensive and practical resource for asthma care and prevention worldwide.
2 de mar. de 2021 · Last year’s Update in Asthma highlighted the need to integrate multidisciplinary advances, leading to better appreciation of epidemiological evidence, new paradigms for effective preventative strategies, and to move treatment focus to the biological underpinnings of asthma.
17 de dic. de 2021 · Tezspire™ is a first-in-class biologic that targets TSLP, an epithelial cytokine, and reduces asthma exacerbations in a broad population of severe asthma patients. It is the first and only biologic for severe asthma without phenotype or biomarker limitations.
